bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.36 USD
-0.01 (-3.64%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $0.36 0.00 (-0.72%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.36 USD
-0.01 (-3.64%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $0.36 0.00 (-0.72%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Zacks News
Novartis CAR-T Therapy Drug Recommended by FDA Panel
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has unanimously (10-0) recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel).
bluebird bio (BLUE) Looks Good: Stock Adds 8.5% in Session
by Zacks Equity Research
bluebird bio saw its shares rise almost 9% on the day on the back of the company's recently released updated results from an ongoing early-stage clinical trial in relapsed/refractory multiple myeloma..
bluebird Stock Up on Positive Interim Multiple Myeloma Data
by Zacks Equity Research
bluebird bio (BLUE) reported encouraging interim phase I data on its anti-BCMA CAR T cell candidate, bb2121, in relapsed/refractory multiple myeloma patients.
Here's Why Bluebird Bio (BLUE) is Rallying Today
by Madeleine Johnson
On Thursday, shares of Bluebird Bio Inc. (BLUE) are rallying, up over 17% in midday trading after positive results came in for its experimental anti-BCMA CAR (chimeric antigen receptor) T-cell product candidate bb2121.
Bear of the Day: Conn's (CONN)
by David Bartosiak
With shoppers moving from bricks to clicks retailers are really struggling
Lessons Of A Biotech Blowup
by Brian Bolan
Biotechs are risky plays, even for the "smart money"